Point-of-care diagnostics firm Nanopath has strengthened its executive management team with the addition of five experts in manufacturing, clinical medicine, product development and commercialization. The new appointees have decades of relevant experience in their respective fields.

“Not only are these individuals expert in their respective fields, they are also highly collaborative, fantastic leaders, and embody the mission and culture of the company” Nanopath Co-Founder/Co-CEO Alison Burklund, Ph.D., said.

Chief Medical Officer Edward Evantash, M.D., will lead Nanopath’s clinical strategy, bridging the gap between science and patient care while also contributing to regulatory and market access strategy. He previously was medical director and vice president of Global Medical Affairs at Hologic for more than a decade, following his role as division chief of general obstetrics and gynecology at Tufts University School of Medicine. Dr. Evantash earned his medical degree from the University of Pennsylvania and completed his residency in gynecology and obstetrics at Johns Hopkins.

“I’m incredibly excited to join team Nanopath,” Dr. Evantash said. “I’m confident that Nanopath’s platform will set a new standard of care—they’ve risen the bar to new heights. I’ve spoken to the leading KOLs [key opinion leaders]in this space, and the enthusiasm for Nanopath’s clinical impact is unmatched.”

Matthew Black, Ph.D., has led Nanopath’s assay development team since 2023 and has now been promoted to chief scientific officer. Since joining Nanopath, he has driven significant advances to the company’s platform, including generating clinical data, decreasing time-to-result, and improving platform sensitivity more than 1,000-fold. Previously, Dr. Black led the development of the first U.S. Food and Drug Administration-authorized at-home molecular test for COVID-19 at Lucira Health, guiding it from feasibility through commercialization. Dr. Black earned a doctorate degree in chemical engineering from the University of California – Santa Barbara.

“I’m excited to take on this role and proud to work with such a passionate team that is redefining how we bring fast, accurate molecular testing closer to patients,” Dr. Black stated.

Matt Cote has led Nanopath’s engineering team since 2022 and is now vice president of engineering. At Nanopath, he has implemented innovative, scalable hardware and software solutions for the company’s novel cartridge-reader system, advancing its performance, reliability, and usability. Cote previously led an interdisciplinary engineering team at Quanterix to advance single molecule protein detection technology. He earned a master’s degree in engineering from the University of Connecticut.

As strategic women’s health advisor, Madeleine Livingston will focus on Nanopath’s women’s health strategy, partnership milestones, and opportunities to maximize the platform’s clinical impact. She brings experience mobilizing payers, employers, and industry to launch programs that deliver measurable economic impact. Livingston is currently the director of strategic partnerships at Thirty Madison and has contributed to national and international initiatives through roles with the Gates Foundation’s Women’s Health Innovation Equity Forum. Livingston earned an MBA from The Tuck School of Business at Dartmouth.

As operations and manufacturing advisor, Christopher Slachta, Ph.D., will support Nanopath’s transition from development to production-scale manufacturing. He brings extensive experience from leadership roles at medical diagnostics companies. He is currently chief operating officer at Cytovale and previously held leadership roles in manufacturing and operations at Abbott and Ortho Clinical Diagnostics. Dr. Slachta earned a doctorate degree in molecular immunology and microbiology from the Lewis Katz School of Medicine at Temple University.

These five new executive team members join Nanopath at a crucial time for the firm. In the last year, the company has expanded from 13 to 20 employees and has achieved significant traction spanning product development, pilot clinical studies, and regulatory activities. 

“Our new leadership, together with our interdisciplinary team, will propel forward Nanopath’s mission to transform diagnostics for women’s health and beyond” Nanopath Co-Founder/Co-CEO Amogha Tadimety, Ph.D., commented.

Nanopath is a women-led company dedicated to improving health equity worldwide, starting with women’s health. Nanopath’s proprietary molecular diagnostic testing platform takes a new approach to the way in which clinicians characterize human health. The company’s biosensing technology can potentially enable fast, high-complexity testing at the point-of-care rather than in centralized laboratories. The company is headquartered in Cambridge, Mass., at The Engine built by MIT, a facility for high-potential, tough-tech startups. Nanopath is backed by Norwest Venture Partners, the Medtech Convergence Fund, Gingerbread Capital, and Green D Ventures.